Adventrx Pharmaceuticals (ANX -3%) says it's commenced dosing in its QT/QTc study of ANX-188....

|By:, SA News Editor

Adventrx Pharmaceuticals (ANX -3%) says it's commenced dosing in its QT/QTc study of ANX-188. The study will assess whether or not the drug has an effect on QT prolongation, which can potentially lead to malignant cardiac rhythm disturbances, as part of an FDA requirement to assess cardiac repolarization for most new drugs having systemic bioavailability. The dosing is expected to be completed in the first quarter, and results ae anticipated in the second quarter of 2013.